S.F. biotech has equity funding epiphany. Firm embracing new model for raising capital

Epiphany Biosciences said it raised $36 million in a private equity round, but management likes to focus less on how much was raised than from whom.

For the San Francisco company’s A round, Epiphany decided to bypass traditional life science venture investors to opt instead for lead investor Wexford Capital LLC, a private equity firm in Greenwich, Conn.

San Francisco Business Times – March 23, 2007
by Daniel S. Levine

Full Story: http://www.bizjournals.com/sanfrancisco/stories/2007/03/26/story17.html?b=1174881600^1436328